Romiplostim (Nplate)
PeptideRomiplostim is a recombinant Fc-peptide fusion protein thrombopoietin receptor agonist. FDA-approved 2008 for chronic ITP, 2018 for pediatric ITP. Phase 3: 88% overall platelet response vs 14% placebo in non-splenectomized patients. Durable response in 52% pediatric patients vs 10% placebo. Weekly SC injection maintains platelets ≥50,000/μL.
Quick Answer
What it is
Romiplostim is a recombinant Fc-peptide fusion protein thrombopoietin receptor agonist. FDA-approved 2008 for chronic ITP, 2018 for pediatric ITP.
Key findings
- Grade A: Durable Platelet Response (Immune Thrombocytopenia)
- Grade A: Overall Platelet Response (Immune Thrombocytopenia)
- Grade A: Long-term Efficacy (Immune Thrombocytopenia)
Safety
- Safe long-term with no increased thrombosis or malignancy risk.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Romiplostim (Nplate)
Quick Facts: Romiplostim (Nplate)
- Best Evidence:Grade A
- Conditions Studied:1
- Research Outcomes:10
- Grade A Findings:4
- Grade B Findings:3
- Key Effect:Immune Thrombocytopenia
A4
B3
C1
D2
1 conditions · 10 outcomes
Detailed Outcomes
A
Durable Platelet Response
Phase 3: 38% durable response (≥50,000/μL for ≥6 of last 8 weeks) in splenectomized vs 0% placebo (P=0.0013). 52% durable response in pediatric patients vs 10% placebo (P=0.002, OR 9.1).
large↑Improves
A
Overall Platelet Response
Phase 3: 88% non-splenectomized and 79% splenectomized achieved platelet response vs 14% and 0% placebo (P<0.0001). Mean 13.8 weeks with platelets ≥50,000/μL vs 0.8 weeks placebo.
large↑Improves
A
Long-term Efficacy
5-year extension: 95% achieved platelet response at least once. Platelet response maintained at median 92% of visits. Stable doses (mean 5-8 μg/kg) with platelets 50-200,000/μL throughout.
large↑Improves
A
Bleeding Reduction
Reduced bleeding events vs placebo. Lower rescue medication use. Decreased need for concurrent ITP therapies. Safe long-term with no increased thrombosis or malignancy risk.
large↓Improves
B
Immune Function
46 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
9 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Anti-Cancer Activity
8 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Reproductive Outcomes
4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
small↑Improves
D
Liver Protection
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Mortality
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves